Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8626 to 8640 of 8992 results

  1. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development Reference number: GID-TA10577 Expected publication date:  21 April 2021

  2. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    Discontinued Reference number: GID-TA11265

  3. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    In development Reference number: GID-MT567 Expected publication date: TBC

  4. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

  5. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development Reference number: GID-TAG499 Expected publication date: TBC

  6. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Discontinued Reference number: GID-TA10694

  7. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    Discontinued Reference number: GID-TA11433

  8. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    Discontinued Reference number: GID-TA11344

  9. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  10. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  11. Improving supportive and palliative care for adults with cancer (CSG4)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  12. Improving outcomes in breast cancer (CSG1)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  13. More than 20,000 people benefitting from innovative migraine pills recommended by NICE

    A new type of tablet specifically designed to prevent migraine is transforming lives across England, with the number of people being prescribed these medicines more than tripling in just one year.

  14. NICE publishes first quality standard to improve care for people with rare diseases

    Ahead of Rare Disease Day on 28 February, we've published our first ever quality standard on rare diseases, and the first to have been developed in partnership with an external organisation.